Tag: intravenous

Baxter International (BAX) appointed John Rogers as CFO, with CEO Andrew Hider temporarily assuming CFO duties. Rogers brings cross-industry experience, potentially influencing capital allocation and reporting. Baxter aims for $12.4B revenue and $788.3M earnings by 2029, requiring 2.8% yearly revenue growth. The company recently launched a $600M tender offer for longer-dated notes, amending its credit agreement. Investors focus on margin stabilization and leverage.

Baxter named John Rogers as its new CFO, effective October 1. Rogers previously served as CFO of Smith & Nephew. Baxter's CEO, Andrew Hider, stated Rogers will aid in stabilizing the business and driving continuous improvement. Rogers' appointment follows Baxter's multiyear restructuring, including the sale of its biopharma and kidney care businesses. Baxter reiterated its 2026 financial outlook.

Baxter said in SEC filings that interim CFO Anita Zielinski will leave in September. She will join Cardinal Health as chief accounting officer and SVP of finance on Nov. 5, with a $750,000 sign-on bonus and $1 million in time-vesting RSUs. Baxter has not named a successor. Baxter recently raised its full-year outlook to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

Baxter International shares rose about 19% this week after the company reported a Q2 earnings beat and raised full-year guidance, according to S&P Global Market Intelligence and Baxter. Q2 sales were $2.96B, up 5% year over year, and GAAP net income rose to $135M. Baxter now expects 2025 sales growth of 3% to 4% and adjusted EPS of $1.95 to $2.15.

Baxter International shares rose about 19% over the week after the company reported encouraging Q2 results. Baxter posted $2.96B revenue, up 5% year over year, and GAAP net income of $135M. Adjusted EPS was $0.56. Analysts expected $2.8B revenue and $0.37 adjusted EPS. Baxter raised FY guidance to 3%-4% sales growth and adjusted EPS of $1.95-$2.15.

US stocks rose as investors digested strong Q2 earnings expectations and results, led by Microsoft. The article cites Bloomberg Intelligence forecasts for Q2 earnings up about 23% and notes 86% of 243 S&P 500 firms beat estimates. It also reports chip and AI-infrastructure gains tied to Lam Research and other semis, while some software names fell.